Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adjuvant for transcutaneous immunization

An adjuvant and immune response technology, applied in the direction of vaccines, biocides, aerosol delivery, etc., can solve the problems that cannot be expected to obtain immune effects

Inactive Publication Date: 2007-07-25
UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SEC OF THE ARMY
View PDF13 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So according to the literature, molecules such as cholera toxin (85,000 daltons) should not be used as they cannot be expected to pass through the skin and therefore cannot be expected to obtain an immune effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant for transcutaneous immunization

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0147] BALB / c mice aged 6 to 8 weeks in a group of 5 mice were immunized percutaneously as described in the "Methods of Immunization" above. Mice were immunized with 100 μl of the immunization solution prepared as follows: the liposomes prepared as described in "Preparation of Liposomes" above were mixed with a salt solution to form liposomes, and then the salt solution (only containing lipids) was used to immunize mice. The group of plastids) or CT dissolved in a salt solution to dilute the pre-formed liposomes to produce an immune solution. Each 100 μl of the solution contains liposomes containing 10-150 mM phospholipids and 100 μg CT. The CT was mixed with a saline solution to prepare an immune solution containing 100 μg CT per 100 μl solution for the CT-only group. Vortex the solution for 10 seconds before inoculation.

[0148] The mice were transcutaneously immunized at 0 and 3 weeks, and 3 weeks after the booster immunization, the antibody level was determined using the ELIS...

Embodiment 2

[0153] BALB / c mice aged 6 to 8 weeks in a group of 5 mice were immunized percutaneously as described in the "Methods of Immunization" above. In week 0 and 3, immunize mice with 100 μl of the immunization solution prepared as follows: mix BSA with saline solution to prepare an immunization solution containing 200 μg of BSA per 100 μl salt solution for use in the BSA-only group; in the salt solution BSA and CT were mixed to prepare an immune solution containing 200 μg BSA and 100 μg CT per 100 μl saline solution for the group receiving BSA and CT. When using liposomes, prepare liposomes as described in "Preparation of liposomes" above, and first mix with salt solution to form liposomes, and then use BSA or BSA+CT diluted in salt solution The formed liposomes are used to produce an immune solution. Each 10 μl of the immune solution contains 50 mM phospholipid liposomes and 200 μg BSA, or each 100 μl of the immune solution also contains 200 μg BSA+100 μg CT. Vortex the solution for 10...

Embodiment 3

[0158] BALB / c mice aged 6 to 8 weeks in a group of 5 mice were immunized percutaneously as described in the "Methods of Immunization" above. In week 0 and 3, mice were immunized with 100 μl of the immune solution prepared as follows: LT was mixed with the saline solution to prepare an immune solution containing 100 μg LT per 100 μl of the salt solution for the LT-only group. When using liposomes, prepare liposomes as described in "Liposome Preparation" above, and first mix with salt solution to form liposomes, and then dilute the pre-formed liposomes with LT in the salt solution In order to produce an immune solution, each 100 μl of the immune solution contains liposomes containing 50 mM phospholipids and 100 μg LT. Vortex the solution for 10 seconds before inoculation.

[0159] Three weeks after the second immunization, the anti-LT antibody was measured using the ELISA described in "ELISA IgG (H+L)" above. The results are shown in Table 3. LT with or without liposomes was obvious...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.

Description

[0001] This application is a divisional application in which the international application PCT / US97 / 21324 entered the Chinese national phase on June 23, 1999, the application number is 97180947.X, and the invention title is "Adjuvant for Transdermal Immunization". Background of the invention [0002] The present invention relates to transdermal immunization and adjuvants that can be used therein to induce antigen-specific immune responses. [0003] Transdermal immunization requires both the antigen to pass through the skin surface barrier that is usually impenetrable, and an immune response to the antigen. U.S. Application No. 08 / 749,164 uses cholera toxin as an antigen, which stimulates a strong antibody response with good reproducibility; the antigen can be applied to the skin in the form of a salt solution, with or without liposomes. This application will demonstrate transdermal immunization using adjuvants, such as bacterial exotoxins and their subunits, and related toxins. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K9/06A61K9/08A61K9/107A61K9/127A61K9/70A61K35/14A61K35/39A61K39/39A61K39/00A01N37/18A61F13/00A61K9/52A61K9/56A61K39/002A61K39/015A61K39/02A61K39/05A61K39/08A61K39/10A61K39/102A61K39/104A61K39/106A61K39/12
CPCA61K2039/55511A61K2039/55544A61K2039/55555A61K9/127A61K35/39A61K9/06A61K35/14A61K2039/55527A61K9/107A61K39/39A61K9/7023A61K9/08A61K2039/53A61K2039/54A61K2039/55566
Inventor G·M·格伦C·R·阿尔文
Owner UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SEC OF THE ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com